in respect of any other Reference Period than set out in paragraph (a) above,
41
The financial covenant in this Clause 15.3 shall apply at all times, by will (unless there is an potential Event of Default) be tested at each Quarter Date by delivery of the compliance certificate pursuant to Clause 14.5 (a) above.
15.4 Equity cure No breach of a financial covenant set out above will be considered to have occurred if a New Shareholder Injection is made within 30 days from the earlier of (i) the Issuer becoming aware of the failure to comply with any Financial Covenant and (ii) delivery of a compliance certificate evidencing such failure to comply, always provided that the relevant Financial Covenant would be complied with if tested for the same Reference Period on the basis that such New Shareholder Injection was deemed to have been made immediately prior to the relevant testing date.
16. GENERAL COVENANTS
Each relevant Party has undertaken the general covenants in this Clause 16 to the Bond Trustee (on behalf of the Bondholders), as further stated below.
The covenants in this Clause 16 shall remain in force from the date of this Bond Agreement and until such time that no amounts are outstanding under this Bond Agreement and any other Finance Document, unless the Bond Trustee (or the Bondholders Meeting, as the case may be), has agreed in writing to waive any covenant, and then only to the extent of such waiver, and on the terms and conditions set forth in such waiver.
16.1 Mergers The Issuer shall not, and shall ensure that no other Group Company shall, carry out any merger or other business combination or corporate reorganization involving consolidating the assets and obligations of the Issuer or such Group Company with any other companies or entities if such transaction would have a Material Adverse Effect. The Issuer shall notify the Bond Trustee of any such transaction, providing relevant details thereof, as well as, if applicable, its reasons for believing that the proposed transaction would not have a Material Adverse Effect.
16.2 De-mergers The Issuer shall not, and shall ensure that no other Group Company shall, carry out any de-merger or other corporate reorganization involving splitting the Group Company into two or more separate companies or entities, if such transaction would have a Material Adverse Effect. The Issuer shall notify the Bond Trustee of any such transaction, providing relevant details thereof, as well as, if applicable, its reasons for believing that the proposed transaction would not have a Material Adverse Effect.
